European Interleukin Inhibitors Market Growth Aspects

Published: May 2021

The European Interleukin Inhibitors market is anticipated to grow significantly at a CAGR of 10.8% over the forecast period (2021-2027). The UK, Germany, France, Italy, Spain, and the Rest of Europe are the key economies contributing to the growth of the market over the forecast period. The key aspect that drives the growth of the European Interleukin Inhibitors market includes the well-established healthcare sector in the region. Besides, the rising prevalence of various diseases such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others across the region. As per the Institute for Health Metrics and Evaluation, the prevalence of psoriasis was 12.3 million in 2017 which increased to 12.4 million in 2019. 

Browse the full report description European Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/europe-interleukin-inhibitors-market

The prevalence of asthma in the region in 2017 was more than 40.3 million which increased to 41.4 million in 2019. Whereas, the prevalence of inflammatory bowel disease (IBD) in 2017 was 1.5 million in 2017 which increased to more than 1.6 million in 2019. Further, the well-established healthcare sector in the region creates scope for market growth. There has been increased adoption of interleukin inhibitors for the treatment of such diseases. The IL-17 inhibitors function as angiogenesis; have a pro-inflammatory role in asthma; increases the inflammatory cytokines; and induces production of IL-4, IL-5, and IL-13, which stimulate eosinophil expansion. Hence, this is likely to drive the market growth over the forecast period.

Market Coverage

  • Market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered- By Product Type and Applications
  • Region Covered- Europe
  • Competitive Landscape- Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among others

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment dominates the market in base year?
  • Which segment will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

European Interleukin Inhibitors Market – Segmentation

By Product Type

  • IL-1 Inhibitors
  • IL-5 Inhibitors
  • IL-6 Inhibitors
  • IL-17 Inhibitors
  • IL-23 Inhibitors

By Applications

  • Arthritis
  • Asthma
  • Eczema
  • Inflammatory Bowel Disease (IBD)
  • Psoriasis
  • Others

European Interleukin Inhibitors Market – Countries Covered

Europe    

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/europe-interleukin-inhibitors-market